ADALVO RECEIVES EU'S MAIDEN GENERIC APPROVAL FOR LIRAGLUTIDE PRE-FILLED PEN

KUALA LUMPUR, June 14 (Bernama) -- Adalvo announced the successful decentralised procedure (DCP) approval for Liraglutide pre-filled pen, marking it the first generic approval in the European Union (EU).

“This achievement reflects Adalvo’s dedication to enhancing diabetes care by providing our partners with high quality, affordable treatment options.

“Securing this approval demonstrates the exceptional capabilities of our team and their commitment to the industry,” said Adalvo Chief Executive Officer, Anil Okay in a statement.

As a bioequivalent version of Victoza pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug achieved global sales exceeding US$4.8 billion in 2023, as reported by IQVIA. (US$1=RM4.71)

The successful development of Liraglutide highlights Adalvo's capability to offer a diverse and comprehensive diabetes portfolio, encompassing both complex peptide injectables and small molecule oral treatments.

Adalvo’s commitment to providing access to high-quality differentiated products while simultaneously navigating manufacturing complexities reinforces its position as a trusted leader in the pharmaceutical industry.

The company is committed to maintaining the highest standards of excellence in all their endeavours and looks forward to continuing to deliver innovative healthcare solutions that make a difference in the lives of patients worldwide.

Adalvo is a global pharmaceutical company, and one of the leading business-to-business (B2B) pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 partners globally.

-- BERNAMA